$DARE
Dare Bioscience, Inc. Stock $dare

$dare Overview Financials Valuation SEC Filings Company Website

2014 Q4 Form 10-Q Financial Statement

#000119312514411131 Filed on November 13, 2014

Income Statement

Concept	2014 Q4	2014 Q3	2013 Q3
Revenue	$0.00	$0.00	$0.00
YoY Change	-100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$2.610M	$2.440M	$1.230M
YoY Change	65.19%	98.37%
% of Gross Profit
Research & Development	$4.701M	$2.928M	$1.586M
YoY Change	226.46%	84.62%
% of Gross Profit
Depreciation & Amortization	$40.00K	$30.00K	$40.00K
YoY Change	0.0%	-25.0%	-85.19%
% of Gross Profit
Operating Expenses	$7.308M	$5.369M	$2.813M
YoY Change	142.39%	90.86%
Operating Profit
YoY Change
Interest Expense	$163.0K	$191.0K	$378.0K
YoY Change	-62.09%	-49.47%
% of Operating Profit
Other Income/Expense, Net	-$159.0K	-$189.0K	-$385.0K
YoY Change	-66.24%	-50.91%
Pretax Income	-$7.470M	-$5.560M	-$3.200M
YoY Change	114.66%	73.75%
Income Tax		$0.00	$0.00
% Of Pretax Income
Net Earnings	-$7.467M	-$5.558M	-$3.198M
YoY Change	114.57%	73.8%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share	-$3.662M	-$2.766M	-$2.238M
COMMON SHARES
Basic Shares Outstanding	20.13M shares	20.12M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2014 Q4	2014 Q3	2013 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$51.17M	$57.79M	$9.910M
YoY Change	832.06%	483.15%
Cash & Equivalents	$51.17M	$57.79M	$9.908M
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses
Receivables	$1.660M	$1.910M	$330.0K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$52.84M	$59.70M	$10.24M
YoY Change	719.54%	482.99%
LONG-TERM ASSETS
Property, Plant & Equipment	$342.0K	$268.0K	$280.0K
YoY Change	39.59%	-4.29%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$215.0K	$120.0K	$140.0K
YoY Change	59.26%	-14.29%
Total Long-Term Assets	$557.0K	$388.0K	$420.0K
YoY Change	46.58%	-7.62%
TOTAL ASSETS
Total Short-Term Assets	$52.84M	$59.70M	$10.24M
Total Long-Term Assets	$557.0K	$388.0K	$420.0K
Total Assets	$53.39M	$60.09M	$10.66M
YoY Change	682.09%	463.66%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.255M	$1.461M	$1.140M
YoY Change	37.31%	28.16%
Accrued Expenses	$3.648M	$1.571M	$1.930M
YoY Change	60.42%	-18.6%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$8.820M
YoY Change	-100.0%	-100.0%
Long-Term Debt Due	$3.120M	$3.350M	$3.070M
YoY Change	-0.32%	9.12%
Total Short-Term Liabilities	$8.061M	$6.379M	$14.96M
YoY Change	-46.78%	-57.36%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$590.0K	$3.930M
YoY Change	-100.0%	-84.99%
Other Long-Term Liabilities	$7.000K	$45.00K	$1.210M
YoY Change	-41.67%	-96.28%
Total Long-Term Liabilities	$7.000K	$1.175M	$5.140M
YoY Change	-99.84%	-77.14%
TOTAL LIABILITIES
Total Short-Term Liabilities	$8.061M	$6.379M	$14.96M
Total Long-Term Liabilities	$7.000K	$1.175M	$5.140M
Total Liabilities	$8.068M	$7.554M	$20.10M
YoY Change	-58.84%	-62.42%
SHAREHOLDERS EQUITY
Retained Earnings	-$121.8M	-$114.3M
YoY Change	23.71%
Common Stock	$167.1M	$2.000K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$45.33M	$52.53M	-$9.450M
YoY Change
Total Liabilities & Shareholders Equity	$53.39M	$60.09M	$10.66M
YoY Change	682.09%	463.66%

Cashflow Statement

Concept	2014 Q4	2014 Q3	2013 Q3
OPERATING ACTIVITIES
Net Income	-$7.467M	-$5.558M	-$3.198M
YoY Change	114.57%	73.8%
Depreciation, Depletion And Amortization	$40.00K	$30.00K	$40.00K
YoY Change	0.0%	-25.0%	-85.19%
Cash From Operating Activities	-$5.610M	-$5.550M	-$3.220M
YoY Change	71.56%	72.36%	-79.84%
INVESTING ACTIVITIES
Capital Expenditures	-$110.0K	-$80.00K	$0.00
YoY Change			-100.0%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$0.00	$0.00
YoY Change
Cash From Investing Activities	-$110.0K	-$80.00K	$0.00
YoY Change			-100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-900.0K	-850.0K	8.050M
YoY Change	-21.74%	-110.56%	-18.36%
NET CHANGE
Cash From Operating Activities	-5.610M	-5.550M	-3.220M
Cash From Investing Activities	-110.0K	-80.00K	0.000
Cash From Financing Activities	-900.0K	-850.0K	8.050M
Net Change In Cash	-6.620M	-6.480M	4.830M
YoY Change	49.77%	-234.16%	-177.78%
FREE CASH FLOW
Cash From Operating Activities	-$5.610M	-$5.550M	-$3.220M
Capital Expenditures	-$110.0K	-$80.00K	$0.00
Free Cash Flow	-$5.500M	-$5.470M	-$3.220M
YoY Change	68.2%	69.88%	-79.71%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2014Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2014Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1798264	shares
CY2014Q3	us-gaap	Long Term Loans Payable LongTermLoansPayable	587000
CY2014Q3	us-gaap	Interest Payable Current And Noncurrent InterestPayableCurrentAndNoncurrent	543000
CY2014Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2014Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	5.71
CY2014Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2014Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2014Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2014Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	20125049	shares
CY2013Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	9908000
CY2014Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	20124764	shares
CY2014Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	20124764	shares
CY2014Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	1011585	shares
CY2014Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	120000000	shares
CY2014Q3	us-gaap	Debt Instrument Interest Rate Stated Percentage DebtInstrumentInterestRateStatedPercentage	0.07	pure
CY2014Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	5.16
CY2014Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	736024	shares
CY2014Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	4.37
CY2014Q3	us-gaap	Preferred Stock Value PreferredStockValue
CY2014Q3	us-gaap	Liabilities Current LiabilitiesCurrent	6379000
CY2014Q3	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	1175000
CY2014Q3	us-gaap	Common Stock Value CommonStockValue	2000
CY2014Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2014Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	1461000
CY2014Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-114314000
CY2014Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1571000
CY2014Q3	us-gaap	Stockholders Equity StockholdersEquity	52532000
CY2014Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	45000
CY2014Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	339000
CY2014Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	60086000
CY2014Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	166844000
CY2014Q3	us-gaap	Loans Payable Current LoansPayableCurrent	3347000
CY2014Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	686000
CY2014Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	57786000
CY2014Q3	us-gaap	Money Market Funds At Carrying Value MoneyMarketFundsAtCarryingValue	57688000
CY2014Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	268000
CY2014Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	488000
CY2014Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	130000
CY2014Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	350000
CY2014Q3	us-gaap	Assets Assets	60086000
CY2014Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	120000
CY2014Q3	us-gaap	Assets Current AssetsCurrent	59698000
CY2014Q3	ceru	Accrued Manufacturing Expenses Current AccruedManufacturingExpensesCurrent	84000
CY2014Q3	ceru	Accounts Receivable Prepaid Expense And Other Current Assets AccountsReceivablePrepaidExpenseAndOtherCurrentAssets	1912000
CY2014Q3	ceru	Accrued Clinical Trial Costs Current AccruedClinicalTrialCostsCurrent	462000
CY2012Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	16707000
CY2013Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	785531	shares
CY2013Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	785531	shares
CY2013Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	120000000	shares
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	3.98
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1062694	shares
CY2013Q4	us-gaap	Temporary Equity Value Excluding Additional Paid In Capital TemporaryEquityValueExcludingAdditionalPaidInCapital	81525000
CY2013Q4	us-gaap	Long Term Loans Payable LongTermLoansPayable	3124000
CY2013Q4	us-gaap	Interest Payable Current And Noncurrent InterestPayableCurrentAndNoncurrent	391000
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	5488000
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	33119	shares
	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	14.5074	pure
CY2013Q4	us-gaap	Money Market Funds At Carrying Value MoneyMarketFundsAtCarryingValue	5233000
CY2013Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2013Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2013Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2013Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2013Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	245000
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	7028000
CY2013Q4	us-gaap	Assets Assets	6827000
CY2013Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	135000
CY2013Q4	us-gaap	Assets Current AssetsCurrent	6447000
CY2013Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2013Q4	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	928000
CY2013Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	618000
CY2013Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	928000
CY2013Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2013Q4	us-gaap	Liabilities Current LiabilitiesCurrent	15146000
CY2013Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	4455000
CY2013Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2013Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	914000
CY2013Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-98439000
CY2013Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2274000
CY2013Q4	us-gaap	Stockholders Equity StockholdersEquity	-94299000
CY2013Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	12000
CY2013Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	379000
CY2013Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	6827000
CY2013Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	4140000
CY2013Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	8824000
CY2013Q4	us-gaap	Loans Payable Current LoansPayableCurrent	3134000
CY2013Q4	ceru	Debt Instrument Accrued Interest DebtInstrumentAccruedInterest	234000
CY2013Q4	ceru	Accrued Manufacturing Expenses Current AccruedManufacturingExpensesCurrent	433000
CY2013Q4	ceru	Accounts Receivable Prepaid Expense And Other Current Assets AccountsReceivablePrepaidExpenseAndOtherCurrentAssets	959000
CY2013Q4	ceru	Accrued Clinical Trial Costs Current AccruedClinicalTrialCostsCurrent	610000
CY2014Q2	us-gaap	Proceeds From Sale Of Machinery And Equipment ProceedsFromSaleOfMachineryAndEquipment	30000
CY2014Q2	us-gaap	Conversion Of Stock Shares Converted1 ConversionOfStockSharesConverted1	6826004	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	2.61
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-13343000
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate		pure
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0108	pure
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	651913	shares
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-20.96
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.79	pure
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-6000
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-812000
	us-gaap	Interest Paid Net InterestPaidNet	522000
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	2289000
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	7000
	us-gaap	Paid In Kind Interest PaidInKindInterest	457000
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	8824000
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4591000
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	240000
	us-gaap	Share Based Compensation ShareBasedCompensation	489000
	ceru	Increase Decrease Accounts Receivable Prepaid Expenses And Other Current Assets IncreaseDecreaseAccountsReceivablePrepaidExpensesAndOtherCurrentAssets	-26000
	us-gaap	Net Income Loss NetIncomeLoss	-13663000
	us-gaap	Investment Income Interest InvestmentIncomeInterest	1000
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	163000
	us-gaap	Interest Expense InterestExpense	1057000
	us-gaap	Operating Expenses OperatingExpenses	12851000
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	8260000
	us-gaap	Federal Income Tax Expense Benefit Continuing Operations FederalIncomeTaxExpenseBenefitContinuingOperations	0
	us-gaap	Straight Line Rent Adjustments StraightLineRentAdjustments	-5000
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-6799000
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-244000
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	6551000
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	16000
	us-gaap	State And Local Income Tax Expense Benefit Continuing Operations StateAndLocalIncomeTaxExpenseBenefitContinuingOperations	0
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-812000
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-7000
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P9Y1M6D
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	3.36
	dei	Document Type DocumentType	10-Q
	dei	Entity Registrant Name EntityRegistrantName	CERULEAN PHARMA INC.
	dei	Trading Symbol TradingSymbol	CERU
	us-gaap	Debt Instrument Convertible Threshold Percentage Of Stock Price Trigger DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger	0.775	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.57	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	3.71
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Incorporation Date Of Incorporation EntityIncorporationDateOfIncorporation	2005-11-28
	us-gaap	Nature Of Operations NatureOfOperations	<div> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td valign="top" width="4%" align="left"><b>1.</b></td> <td valign="top" align="left"><b>NATURE OF BUSINESS AND OPERATIONS</b></td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt"> <b>Nature of Business</b> — Cerulean Pharma Inc. (the “Company”) was incorporated on November 28, 2005 as a Delaware corporation and is located in Cambridge, Massachusetts. The Company was formed to develop novel, nanotechnology-based therapeutics in the areas of oncology and other diseases. During 2013, the Company formed a wholly-owned subsidiary, Cerulean Pharma Australia Pty Ltd, as an Australian-based proprietary limited company. The activity in the subsidiary to date has been insignificant.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt"> <b>Basis of Presentation —</b> The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary. All intercompany accounts and transactions have been eliminated. The consolidated interim financial statements of the Company included herein have been prepared, without audit, pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted from this report, as is permitted by such rules and regulations. Accordingly, these condensed consolidated financial statements should be read in conjunction with the Company’s audited financial statements as of and for the year ended December 31, 2013 and notes thereto, included in the Company’s prospectus filed with the SEC pursuant to Rule 424(b)(4) on April 14, 2014 (the “Prospectus”).</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt"> The unaudited condensed consolidated financial statements have been prepared on the same basis as the audited consolidated financial statements. In the opinion of the Company’s management, the accompanying unaudited interim consolidated financial statements contain all adjustments that are necessary to present fairly the Company’s financial position as of September 30, 2014 and the results of its operations for the three and nine months ended September 30, 2014 and 2013 and cash flows for the nine months ended September 30, 2014 and 2013. Such adjustments are of a normal and recurring nature. The results for the nine months ended September 30, 2014 are not indicative of the results for the year ending December 31, 2014, or for any future period.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt"> On April 15, 2014, the Company completed the sale of 8,500,000 shares of its common stock in its initial public offering, or the IPO, at a price to the public of $7.00 per share. On May 7, 2014 the Company completed the sale of an additional 1,069,715 shares of common stock at a price to the public of $7.00 per share under a partial exercise by the underwriters of their option to purchase additional shares of common stock. The sale of the shares to the public resulted in net proceeds to the Company of $59.9 million after deducting underwriting discounts and commissions and offering expenses payable by the Company.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt"> The Company’s board of directors and stockholders approved a 1- for-14.5074 reverse stock split of the Company’s common stock effective March 31, 2014. All share and per share amounts in the consolidated financial statements contained herein and notes thereto have been retroactively adjusted, where necessary, to give effect to this reverse stock split. In connection with the closing of the IPO, all of the Company’s outstanding redeemable convertible preferred stock and convertible notes automatically converted into shares of common stock as of April 15, 2014, resulting in the issuance by the Company of an additional 9,728,237 shares of common stock. The significant increase in shares outstanding in April 2014 is expected to impact the year-over-year comparability of the Company’s net loss per share calculations over the next year.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt"> In connection with the completion of the IPO on April 15, 2014, the Company’s outstanding warrants to purchase 1,857,226 shares of the Company’s preferred stock automatically converted into warrants to purchase an aggregate of 128,663 shares of the Company’s common stock and, as a result, the Company reclassified the warrant liability to additional paid-in capital.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 18pt; MARGIN-TOP: 0pt">  </p> </div>
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-13453000
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate		pure
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5980000
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0183	pure
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y10M24D
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	4.85
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2014
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	140000
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	40000
	us-gaap	State And Local Income Tax Expense Benefit Continuing Operations StateAndLocalIncomeTaxExpenseBenefitContinuingOperations	0
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-204000
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-76000
	us-gaap	Paid In Kind Interest PaidInKindInterest	329000
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	8312000
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	809970	shares
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P6Y1M6D
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	12598425	shares
	dei	Document Period End Date DocumentPeriodEndDate	2014-09-30
	us-gaap	Initial Offering Period InitialOfferingPeriod	April 15, 2014
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	6.61
	dei	Entity Central Index Key EntityCentralIndexKey	0001401914
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.26
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.60	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0200	pure
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	41281	shares
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	30000
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-2904000
	us-gaap	Interest Paid Net InterestPaidNet	326000
	us-gaap	Revenues Revenues	80000
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	2486000
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	116000
	us-gaap	Net Income Loss NetIncomeLoss	-15875000
	us-gaap	Investment Income Interest InvestmentIncomeInterest	5000
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-2493000
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	93000
	us-gaap	Interest Expense InterestExpense	920000
	us-gaap	Operating Expenses OperatingExpenses	13051000
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	7071000
	us-gaap	Federal Income Tax Expense Benefit Continuing Operations FederalIncomeTaxExpenseBenefitContinuingOperations	0
	us-gaap	Straight Line Rent Adjustments StraightLineRentAdjustments	33000
	us-gaap	Undistributed Earnings Loss Allocated To Participating Securities Diluted UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted	0
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	52298000
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-504000
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	65827000
CY2013Q3	us-gaap	State And Local Income Tax Expense Benefit Continuing Operations StateAndLocalIncomeTaxExpenseBenefitContinuingOperations	0
CY2014Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.28
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	547000
	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	59861000
	us-gaap	Share Based Compensation ShareBasedCompensation	628000
	ceru	Increase Decrease Accounts Receivable Prepaid Expenses And Other Current Assets IncreaseDecreaseAccountsReceivablePrepaidExpensesAndOtherCurrentAssets	963000
CY2013	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y2M12D
CY2013	us-gaap	Fair Value Assumptions Expected Dividend Rate FairValueAssumptionsExpectedDividendRate		pure
CY2013Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0	shares
CY2013Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	726987	shares
CY2013Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-4.40
CY2013Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-385000
CY2013Q3	us-gaap	Net Income Loss NetIncomeLoss	-3198000
CY2013Q3	us-gaap	Interest Expense InterestExpense	378000
CY2013Q3	us-gaap	Operating Expenses OperatingExpenses	2813000
CY2013Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1586000
CY2013Q3	us-gaap	Federal Income Tax Expense Benefit Continuing Operations FederalIncomeTaxExpenseBenefitContinuingOperations	0
CY2013Q3	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	7000
CY2013Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1227000
CY2014Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.57	pure
CY2014Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	2.41
CY2014Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate		pure
CY2014Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y
CY2014Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	20124574	shares
CY2014Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0186	pure
CY2014Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.60	pure
CY2014Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0200	pure
CY2014Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-189000
CY2014Q3	us-gaap	Net Income Loss NetIncomeLoss	-5558000
CY2014Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	2000
CY2014Q3	us-gaap	Interest Expense InterestExpense	191000
CY2014Q3	us-gaap	Operating Expenses OperatingExpenses	5369000
CY2014Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2928000
CY2014Q3	us-gaap	Federal Income Tax Expense Benefit Continuing Operations FederalIncomeTaxExpenseBenefitContinuingOperations	0
CY2014Q3	us-gaap	State And Local Income Tax Expense Benefit Continuing Operations StateAndLocalIncomeTaxExpenseBenefitContinuingOperations	0
CY2014Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2441000

Files In Submission

Name	View Source	Status
0001193125-14-411131-index-headers.html	Edgar Link	pending
0001193125-14-411131-index.html	Edgar Link	pending
0001193125-14-411131.txt	Edgar Link	pending
0001193125-14-411131-xbrl.zip	Edgar Link	pending
ceru-20140930.xml	Edgar Link	completed
ceru-20140930.xsd	Edgar Link	pending
ceru-20140930_cal.xml	Edgar Link	unprocessable
ceru-20140930_def.xml	Edgar Link	unprocessable
ceru-20140930_lab.xml	Edgar Link	unprocessable
ceru-20140930_pre.xml	Edgar Link	unprocessable
d802413d10q.htm	Edgar Link	pending
d802413dex102.htm	Edgar Link	pending
d802413dex103.htm	Edgar Link	pending
d802413dex104.htm	Edgar Link	pending
d802413dex105.htm	Edgar Link	pending
d802413dex311.htm	Edgar Link	pending
d802413dex312.htm	Edgar Link	pending
d802413dex321.htm	Edgar Link	pending
d802413dex322.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$DARE
Dare Bioscience, Inc. Stock $dare

2014 Q4 Form 10-Q Financial Statement

#000119312514411131 Filed on November 13, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$DARE Dare Bioscience, Inc. Stock $dare

2014 Q4 Form 10-Q Financial Statement

#000119312514411131 Filed on November 13, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$DARE
Dare Bioscience, Inc. Stock $dare